A detailed history of Boston Family Office LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Boston Family Office LLC holds 746 shares of VRTX stock, worth $323,778. This represents 0.02% of its overall portfolio holdings.

Number of Shares
746
Previous 796 6.28%
Holding current value
$323,778
Previous $354,000 17.51%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

SELL
$366.54 - $479.53 $18,327 - $23,976
-50 Reduced 6.28%
746 $292,000
Q2 2025

Aug 13, 2025

BUY
$421.16 - $509.5 $145,300 - $175,777
345 Added 76.5%
796 $354,000
Q1 2025

May 13, 2025

SELL
$402.49 - $513.76 $40,249 - $51,376
-100 Reduced 18.15%
451 $219,000
Q4 2024

Feb 12, 2025

SELL
$396.64 - $516.74 $5,949 - $7,751
-15 Reduced 2.65%
551 $222,000
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $260,360 - $286,271
566 New
566 $263,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Boston Family Office LLC Portfolio

Follow Boston Family Office LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Family Office LLC with notifications on news.